    IRF5 Degradation Demonstrated Generally Better Outcomes than Approved
    or Clinically Active Drugs in NZBW1 Spontaneous1 Mouse Lupus Model
                                                                           Early, Sustained and Complete                                                Superior Activity Reducing
                    Decreased Proteinuria
                                                                           Reduction in Anti-dsDNA Abs                                                   Anti-dsDNA at Week 37




                                                        ****
                                                        ****                                                                                                             **           ***
                                                                                                                            #
                                                                                                                                                            ** **        *
                                                                                                                                                   le                 5 0 eg r
                                                                                                                                                                            m ade
                                                                                                                                                   ic             IR F5        g/ rkg
                                                                                                                                               eh                   1 5 eg D
                                                                                                                                                                        0 ra
            ****p<0.0001                                                                                                                       V                       A    m de
                                                                                                                                                                               g/ rk
                                                                                                                                                                          f im g
                                                                                                                                                                      1 0 et
                                                                                                                                                        D   D  eu cr av     m o ra
                                                                                                                                                                               g/ nkg
                                                                                                                                                    F5                  ac   it i
                                                                                                                                                                            m ib 3n
                                                                                                                                                   IR    C
                                                                                                                                                                  A nt i- I FN
                                                                                                                                                                               g/ 0kg
                                                                                                                                                           yc lo ph         m R2  A
                                                                                                                                                                               g/ 0
                                                                                                                                                                    os ph          kg
     Vehicle p.o. QD                  IRF5 Degrader 150 mg/kg p.o. QD   Deucravacitinib 30 mg/kg p.o. QD   Cyclophosphamide 50 mg/kg i.p. QW
                                                                                                                                                                            am    id
                                                                                                                                                                            m e5
                                                                                                                                                                               g/ 0kg
     IRF5 Degrader 50 mg/kg p.o. QD   Afimetoran 10 mg/kg p.o. QD       Anti-IFNAR 20 mg/kg s.c. 2x/week                                                                      **p<0.0001, ***p>0.01




•    IRF5 degrader, dosed once a day for 107 days, leading to 80% and >90% IRF5 degradation, led to decreased proteinuria and near complete
     reduction of serum anti-dsDNA Abs superior to standard of care, approved and clinically active agents tested
•    Significantly reduces key interferon genes (OAS1, IFIT1, IF44) at 150mg/kg in the blood from NZB.W1 mice comparable to other test agents



                                                                                                                                                                                                      47
